Literature DB >> 9278213

The effect of age on plasma MEGX concentrations.

R Orlando1, P Palatini.   

Abstract

AIMS: The study was designed to assess the effect age on the monoethylglycinexylidide (MEGX) liver function test.
METHODS: Plasma MEGX concentration was measured in 16 young and 17 elderly healthy volunteers 10, 15, 30, 45 and 60 min after intravenous injection of 1 mg kg(-1) lignocaine.
RESULTS: Lower MEGX concentrations were noted in elderly subjects. The difference between young and old individuals became increasingly significant as the sampling time was increased, mainly because of a progressive decrease in intersubject variability within each of the two study groups. Linear regression analysis consistently showed that the strength of the relationships between MEGX concentration and age increased with increased sampling time and was maximal at 60 min (r = -0.70; P < 0.0001; reduction in MEGX formation (95% CI) 0.51 (0.33-0.69) ng ml(-1) per year).
CONCLUSIONS: These data indicate that the rate of MEGX production declines significantly with age. Therefore, when the results of the MEGX test are to be compared in different study groups, subjects should be strictly matched for age.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9278213      PMCID: PMC2042827          DOI: 10.1046/j.1365-2125.1997.00651.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  3 in total

1.  Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.

Authors:  Gregory T Everson; Mitchell L Shiffman; John C Hoefs; Timothy R Morgan; Richard K Sterling; David A Wagner; Shannon Lauriski; Teresa M Curto; Anne Stoddard; Elizabeth C Wright
Journal:  Hepatology       Date:  2012-03-01       Impact factor: 17.425

2.  Formation of monoethylglycinexylidide (MEGX) in clinically healthy dogs.

Authors:  Stephan Neumann; Meike Frenz; Frank Streit; Michael Oellerich
Journal:  Can J Vet Res       Date:  2011-10       Impact factor: 1.310

3.  Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.

Authors:  Rocco Orlando; Pierpaolo Piccoli; Sara De Martin; Roberto Padrini; Pietro Palatini
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.